PM decides to provide financial support for COVIVAC vaccine trials

Illustrative image (Photo: VNA)

Hanoi (VNA) – The Prime Minister has decided to use
over 8.8 billion VND from the national vaccine fund to support the
first and second phase of clinical trials of , which has been developed
by the Health Ministry’s Institute of Vaccines and Medical
Biologicals (IVAC) since May 2020.

COVIVAC uses viral vector technology on primary
chicken embryo cell culture – a technique IVAC used previously to successfully
produce seasonal flu vaccines. It is preserved at temperatures from 2-8 degrees
Celsius. 

In the first phase, it was evaluated as safe,
well-tolerant and immunogenic.

The second phase will be carried out in Vu Thu district, northern Thai
Binh province, with 375 volunteers.

COVIVAC is the second “made-in-Vietnam” vaccine to be allowed
for clinical trials by the Health Ministry, following Nanogen company’s
NanoCovax./.